Jazz Pharmaceuticals plc
JAZZ
Market Cap$6.85B
Close$
$126.07
14.9% upside
Current Fair Value
14.9% upsideUndervalued by 14.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.85 Billion |
|---|---|
| Enterprise Value | $11.25 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $6.55 |
| Beta | 0.57 |
| Outstanding Shares | 62,882,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 17.66 |
|---|---|
| PEG | 28.76 |
| Price to Sales | 1.77 |
| Price to Book Ratio | 1.86 |
| Enterprise Value to Revenue | 2.88 |
| Enterprise Value to EBIT | 17.31 |
| Enterprise Value to Net Income | 28 |
| Total Debt to Enterprise | 0.51 |
| Debt to Equity | 1.53 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Jazz Pharmaceuticals plc
1,210 employeesJazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration approved drug Xyrem , the sodium salt of...